Technologieangebote

Multitarget Pyridinyliden Hydrazone zur Behandlung der Alzheimer Erkrankung

It was surprisingly found that the pyridinylidene hydrazone derivatives inhibit AChE and BuChE as well as Aβ fibril formation significantly. They can destroy already formed fibrils. And they are able to cross the blood-brain barrier which is thought to be due to their pKa values and lipophilicity.

Weitere Informationen: PDF

Bayerische Patentallianz GmbH
Tel.: +49 89 5480177-0

Ansprechpartner
Peer Biskup

Kommentare (0)

Schreiben Sie einen Kommentar